Mimedis uses 3D printing to manufacture patient specific implants and templates. Mimedis focuses on patient specific solutions, especially for cranio-maxillofacial surgery. Based on an in-house developed innovative software, Mimedis supports various hospitals in Switzerland and Germany with preoperative planning as well as manufacturing of 3D models for individualized surgical treatment solutions, e.g. bone implants or cutting and drill guide templates.
Missing: Mimedis's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Mimedis's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Mimedis News
Jul 6, 2017
Medartis acquires medtech start-up Mimedis 06.07.2017 09:02 Exit Corporate Innovation Basel-based medtech company Medartis has acquired Mimedis, a Swiss medical device start-up company. Mimedis uses 3D printing to manufacture patient specific implants and templates. With effect of 05.07.2017, Medartis has acquired 100% ownership of Mimedis AG , a Swiss medical device start-up company located in Basel. As a result of this acquisition, Medartis will in future be able to offer preoperative planning solutions as well as patient specific implants. The parties have agreed not to disclose financial terms and other conditions of the transaction. Mimedis focuses on patient specific solutions, especially for cranio-maxillofacial surgery. Based on an in-house developed innovative software, Mimedis supports various hospitals in Switzerland and Germany with preoperative planning as well as manufacturing of 3D models for individualized surgical treatment solutions, e.g. bone implants or cutting and drill guide templates. Mimedis is the first successful start-up company resulting from the cooperation of the School of Life Sciences at the University of Applied Sciences and Arts Northwestern Switzerland (FHNW) and the University Hospital Basel. For Mimedis, the merger is an opportunity to make the Mimedis technologies accessible to a broader market. Ralf Schumacher, CEO of Mimedis: «The extensive market presence of Medartis and the integration of our digital product range will allow for a larger number of patients to benefit from individualized implant solutions.» Willi Miesch, CEO of Medartis: «The progressive digitalization modifies also medical treatment. Thus, preoperative planning for surgery is becoming increasingly relevant. Mimedis’ planning software ideally complements Medartis’ product portfolio. This includes both planning of complex interventions with our craniofacial MODUS implants as well as patient specific implants not included in the standard portfolio.» About Medartis Founded in 1997 and headquartered in Basel, Medartis AG is one of the world’s leading manufacturers and providers of medical devices for surgical fixation of bone fractures and osteotomies for the craniofacial region as well as for upper and lower extremities. In 2016, Medartis employed over 360 people worldwide and achieved a turnover of almost CHF 100 Mio. Medartis is represented worldwide in ten markets with its own sales force and in over 35 countries through a broad distributor network. For patients’ welfare, Medartis is committed to providing surgeons and operating theatre personnel with most innovative titanium implants and instruments as well as best in class services that represent advances in osteosynthesis. –
Mimedis Frequently Asked Questions (FAQ)
Where is Mimedis's headquarters?
Mimedis's headquarters is located at Hochbergerstrasse 60c, Basel.
What is Mimedis's latest funding round?
Mimedis's latest funding round is Acquired.
Who are the investors of Mimedis?
Investors of Mimedis include Medartis.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.